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Transcriptomic profiling of the immune response induced by vaccine adjuvants is of critical 
importance for the rational design of vaccination strategies. In this study, transcriptomics 
was employed to profile the effect of the vaccine adjuvant used for priming on the immune 
response following re-exposure to the vaccine antigen alone. Mice were primed with 
the chimeric vaccine antigen H56 of Mycobacterium tuberculosis administered alone or 
with the CAF01 adjuvant and boosted with the antigen alone. mRNA sequencing was 
performed on blood samples collected 1, 2, and 7 days after priming and after boosting. 
Gene expression analysis at day 2 after priming showed that the CAF01 adjuvanted vac-
cine induced a stronger upregulation of the innate immunity modules compared with the 
unadjuvanted formulation. The immunostimulant effect of the CAF01 adjuvant, used in the 
primary immunization, was clearly seen after a booster immunization with a low dose of 
antigen alone. One day after boost, we observed a strong upregulation of multiple genes in 
blood of mice primed with H56 + CAF01 compared with mice primed with the H56 alone. 
In particular, blood transcription modules related to innate immune response, such as 
monocyte and neutrophil recruitment, activation of antigen-presenting cells, and interferon 
response were activated. Seven days after boost, differential expression of innate response 
genes faded while a moderate differential expression of T  cell activation modules was 
appreciable. Indeed, immunological analysis showed a higher frequency of H56-specific 
CD4+ T cells and germinal center B cells in draining lymph nodes, a strong H56-specific 
humoral response and a higher frequency of antibody-secreting cells in spleen of mice 
primed with H56 + CAF01. Taken together, these data indicate that the adjuvant used 
for priming strongly reprograms the immune response that, upon boosting, results in a 
stronger recall innate response essential for shaping the downstream adaptive response.
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inTrODUcTiOn
Vaccines based on purified antigens are often poorly immunogenic and need to be formulated with 
adjuvants or delivery systems, to increase the amount, quality, and duration of the immune response 
to vaccination as well as to ensure long-lived immunological memory and protection (1). Adjuvants 
are substances capable of enhancing and properly skewing the immune responses to the vaccine 
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antigen, and their choice can dramatically affect the type and 
the magnitude of the adaptive immune response to the vaccine 
antigen, by impacting on the innate response starting signal (2).
Profiling the mode of action of different adjuvants is of critical 
importance for the rational design of vaccination strategies, based 
on heterologous combinations of vaccine formulations for prim-
ing and boosting, and for predicting the protective potential of an 
adjuvant for a given vaccine antigen (3–8). The immune profile and 
efficacy of five different adjuvants, combined with vaccine anti-
gens from Mycobacterium tuberculosis, influenza, and Chlamydia, 
were tested in murine infection models within the ADITEC pro-
ject on advanced immunization technologies (6, 9). We have also 
characterized the antigen-specific T and B  cell responses after 
both parenteral and mucosal priming with vaccine formulations 
including different adjuvants or delivery systems, and combining 
heterologous prime-boost schedules, demonstrating the crucial 
role of both the immunization route and vaccine composition 
(3, 5, 10–13).
A systems biology approach, integrating gene expression data 
with immunological results, has been used to study the human 
response to different vaccines (14–26). Systems biology is an 
interdisciplinary approach to analyze multiple data types related 
to complex biological interactions by using computational analy-
sis and mathematical modeling. The systems biology approach 
was first applied to characterize the immune response elicited 
by the yellow fever vaccine YF-17D in humans (23) and, more 
recently, to a variety of other vaccines including the study of 
adjuvanted and non-adjuvanted influenza vaccines in adults (21) 
and children (22, 27).
This approach has been recently applied to investigate the 
priming properties of different vaccine adjuvants at early time 
points after priming in the mouse model, using genome wide 
microarrays, and identified shared blood gene modules enriched 
in T follicular helper and germinal center responses (28). 
Mathematical models have been also developed to predict the 
probability of antigen-specific CD4+ T cells to expand and dis-
seminate in vivo into other secondary lymphoid organs following 
primary immunization with adjuvanted vaccine formulations 
(29, 30).
CAF01 is a promising vaccine adjuvant that has been tested 
in five phase I clinical trials, administered in combination with 
four different antigens including the H56 tuberculosis (TB) 
vaccine antigen (Clinical trial no. NCT00922363), to evaluate 
its safety, tolerability, and immunogenicity. CAF01 is a liposo-
mal adjuvant system composed of cationic liposome vesicles 
[dimethyldioctadecylammonium (DDA)] combined with a 
synthetic variant of cord factor of the mycobacterial cell wall 
[trehalose 6,6-dibehenate (TDB)], which was shown to activate 
macrophages and dendritic cells (DCs) through a specific innate 
activation program via Syk–Card9–Bcl10–Malt1 (31). CAF01 
promotes vaccine depot formation, prolonging the release of 
antigens and stimulating the induction of T follicular helper 
cells into the draining lymph nodes (dLN), together with com-
bined Th1 and Th17 responses and the generation of a robust, 
long-lived memory response in mice (32–34). CAF01 has been 
used as a component of a promising TB vaccine candidate in 
combination with the chimeric antigen H56 of M. tuberculosis 
consisting of the antigen Ag85B fused to the 6-kDa early secre-
tory antigenic target and the latency-associated protein Rv2660c 
(35, 36). The phase I clinical trials showed that CAF01 is safe and 
induces a strong cell-mediated immune response in addition to 
antibodies in humans (37, 38).
In this work, we have analyzed, through a systems biology 
approach, how the CAF01 adjuvant, combined with the H56 
antigen used for priming, programs the immune response 
to downstream re-exposure to the same antigen. Mice were 
primed with H56 + CAF01 or H56 alone and boosted with the 
H56 antigen. A very low antigen dose was used for the boost 
to select antigen-specific clones of T and B cells and to mimic 
the challenge with the pathogen. RNA sequencing was used to 
characterize the blood transcriptome at several time points (1, 2, 
and 7 days) both after priming and after boosting, allowing us to 
follow the transcriptomic profile of the same animals over time. 
Transcriptomic data were analyzed together with immunological 
data on both cellular (antigen-specific CD4+ T cells and germinal 
center B cells in dLN) and humoral responses (quantification of 
H56-specific IgG up to 7 weeks after boost). These studies char-
acterize, for the first time, using a systems biology approach, the 
modulation of the response elicited after prime-boost vaccination 
with the CAF01 adjuvant.
MaTerials anD MeThODs
Mice
Seven-week-old female C57BL/6 mice, purchased from Charles 
River (Lecco, Italy), were housed under specific pathogen-free 
conditions in the animal facility of the Laboratory of Molecular 
Microbiology and Biotechnology (LA.M.M.B.), Department 
of Medical Biotechnologies at University of Siena, and treated 
according to national guidelines (Decreto Legislativo 26/2014). 
All animal studies were approved by the Italian Ministry of Health 
with authorization no. 1004/2015-PR on September 22 2015.
experimental Design
Mice were subcutaneously primed with the chimeric TB vaccine 
antigen H56 administered alone or in combination with the lipo-
some system CAF01, and boosted after 4 weeks with H56 antigen 
alone (Figure 1). Both the innate and adaptive immune responses 
elicited by the two vaccine formulations were explored. T and 
B cells responses were characterized 10 days after boosting (day 
38) within the local dLN and spleen, while the induction of H56-
specific IgG serum response was followed at different time points, 
up to 7 weeks post boost (day 77). In parallel, other groups of 
mice were immunized with the same vaccine schedule described 
earlier, and the molecular signature of the vaccine formulations 
was explored by sequencing RNA from blood at early time points 
(1, 2, and 7 days) after primary and secondary immunizations, 
and thus following the transcriptomic profile over time without 
sacrificing the animal (Figure 1).
immunizations
Groups of four to five mice were immunized by the subcutaneous 
route at the base of the tail. Vaccine formulations consisted of 
FigUre 1 | Study design and samples collection. C57BL/6 mice were 
subcutaneously primed with H56 antigen alone or combined with CAF01, 
and boosted at day 28 with H56. Blood samples were collected at days 0, 
14, 28, 38, 56, and 77 for antibody analysis (Ab) and at days 0, 1, 2, 7, 29, 
30, and 35 (corresponding to days 1, 2, and 7 after boosting) for gene 
expression (Gene Exp). dLN and spleens were collected at days 0 and 38 
(10 days after boosting) to evaluate the secondary CD4+ T and B cell 
responses.
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the chimeric TB vaccine antigen H56 (2 μg/mouse for priming, 
0.5 μg/mouse for boosting; Statens Serum Institut, Denmark), 
administered alone or combined with the adjuvant CAF01 
(250 µg DDA and 50 µg TDB) per mouse (Statens Serum Institut, 
Denmark). Vaccine formulations containing CAF01 were 
injected in a volume of 150 μl/mouse of 10 mM Tris buffer, while 
formulations containing H56 alone in a volume of 100 μl/mouse 
of PBS. Mice primed with both H56 + CAF01 or H56 alone were 
boosted with H56 antigen 4 weeks later.
Blood sample collection
For antibody analysis, blood samples were taken by temporal 
plexus bleed on days 0, 14, 28, 38, 56, and 77 after primary immu-
nization. Blood was incubated for 30 min at 37°C, centrifuged at 
1,200 × g at 4°C for 15 min, and then serum was collected and 
stored at −80°C until further analysis.
For transcriptomic analysis, blood samples were collected from 
individual mice on days 1, 2, 7, 28, 29, 30, and 35 after priming. 
Blood (200 µl) was mixed in a 1:2.8 ratio with PaxGene reagent, in 
a 2 ml Biosphere Eppendorf tube (39, 40). The tube was inverted 
five times and incubated at room temperature for 2  h before 
freezing at −80°C. Total RNA was extracted using the PaxGene 
blood RNA kit (Qiagen, Germany) following manufacturer’s 
instructions and resuspended in 60 µl of BR5 buffer. RNA was 
quantified using (i) the total RNA nano kit on a 2100 Bioanalyzer 
(Agilent Technologies, USA), (ii) the RNA broad range kit on a 
Qubit 2.0 (Thermo Fisher, USA), and (iii) the Nanophotometer 
(Implen, Germany).
illumina sequencing
Libraries were prepared using TruSeq stranded RNA reagents 
(Illumina, USA) according to manufacturer’s instructions, using 
500 ng of total RNA input per sample with dual indexing to enable 
all libraries to be sequenced in the same run. Pooled libraries were 
sequenced on four runs of an Illumina NextSeq 500 instrument 
with 75 bp single end reads. Image analysis and base calling were 
performed using Illumina’s RTA software version 2.4.11 and 
bcl2fastq version 2.18.0.12. Reads were filtered to remove those 
with low base call quality using Illumina’s default chastity criteria. 
Raw sequence data were deposited in Sequence Read Archive 
under Bioproject number PRJNA437839.
Multiparametric Flow cytometric analysis
B and T responses were analyzed in dLN (sub iliac, medial, and 
external). Samples were mashed onto 70 µm nylon screens (Sefar 
Italia, Italy) and washed two times in complete RPMI medium 
(cRPMI, Lonza, Belgium) containing with 100 U/ml penicillin/
streptomycin and 10% fetal bovine serum (Gibco, USA). Samples 
were treated with red blood cells lysis buffer according to manu-
facturer instruction (eBioscience, USA). Cells were incubated 
for 30 min at 4°C in Fc-blocking solution [cRPMI medium with 
5  µg/ml of CD16/CD32 mAb (clone 93; eBioscience, USA)]. 
To evaluate germinal center B  lymphocytes from dLN, cells 
were stained with AF700-conjugated anti-CD45R (anti-B220, 
clone RA3-6B2; BD Biosciences), BV421-conjugated anti-GL7 
(clone GL7; BD Biosciences), and PE-Cy7-conjugated anti-
CD95 (clone Jo2; eBioscience). To evaluate H56-specific CD4+ 
T lymphocytes, cells from dLN were stained for 1 h at RT with 
PE-conjugated I-A(b) M. tuberculosis Ag85B precursor 280–294 
(FQDAYNAAGGHNAVF) tetramer (kindly provided by NIH 
MHC Tetramer Core Facility, Emory University, Atlanta, GA, 
USA), washed and surface stained with HV500-conjugated anti-
CD4 (clone RM4-5; BD Biosciences), and BV786-conjugated 
anti-CD44 (clone IM-7; BD Biosciences). Samples were labeled 
with Live/Dead Fixable Near-IR Stain Kit according to manufac-
turer’s instructions (Invitrogen, USA). All antibodies and tetram-
ers were titrated for optimal dilution. Approximately 5–10 × 105 
cells were acquired on a LSRFortessaTM X-20 flow cytometer (BD 
Biosciences). Data analysis was performed using FlowJo v10 
(TreeStar, USA).
igg elispot
Antibody-secreting cells (ASC) were evaluated in the spleen by 
ELISpot PLUS for mouse IgG kit (Mabtech) 10 days post boost. 
Multiscreen filter (PVDF) plates (Millipore, USA) were pre-wet 
for 2 min with EtOH 70%, washed with sterile dH2O and coated 
with H56 (5 µg/ml) diluted in PBS (Sigma-Aldrich) for the detec-
tion of antigen-specific IgG. After incubation overnight at 4°C, 
the coated wells were washed with sterile PBS and blocked for 
30 min with serum free CTL-Test B culture medium (CTL, USA) 
supplemented with 1% l-glutamine (Sigma-Aldrich, USA). After 
removal of the blocking medium, 1 × 106 cells/well were added 
in a volume of 100  µl of CTL-Test B medium for the analysis 
of H56-specific IgG ASC. Each sample was assayed in triplicate, 
and the plates were incubated overnight for 20  h at 37°C in a 
humidified atmosphere with 5% CO2. After incubation, cells 
were removed by washing with PBS and 100 µl/well of anti-IgG 
biotinylated detection antibody (Mabtech, Sweden), diluted to 
1 µg/ml in PBS containing 0.5% fetal calf serum (FCS, Gibco), 
was added. After incubation for 2 h at room temperature followed 
by washing steps, ELISpot plates were incubated with 50  µl/
well of streptavidin–horseradish peroxidase (Mabtech) diluted 
1:1,000 for 1 h at room temperature. Plates were washed again 
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with PBS, and then 100 µl/well TMB substrate solution (Mabtech) 
was added for approximately 10 min. The reaction was stopped 
by extensive washing in dH2O, and plates were then dried in the 
dark at room temperature. The number of spots was determined 
by plate scanning and analysis services performed at Cellular 
Technology Limited (Germany).
enzyme-linked immunosorbent assay 
(elisa)
Serum H56-specific IgG were quantified by ELISA at different 
time points. Flat bottomed Maxisorp microtiter plates (Nunc, 
Denmark) were coated with H56 (0.5 µg/ml) for 3 h at 37°C and 
overnight at 4°C in a volume of 100 μl/well. Plates were washed 
and blocked with 200 µl/well of PBS containing 1% BSA (Sigma-
Aldrich) for 2 h at 37°C. Serum samples were added (100 μl/well) 
and titrated in twofold dilution in duplicate in PBS supplemented 
with 0.05% Tween 20 and 0.1% BSA (diluent buffer). After incu-
bation for 2 h at 37°C, samples were incubated with the alkaline 
phosphatase-conjugate goat anti-mouse IgG (100 μl/well diluted 
1:1,000 in diluent buffer, Southern Biotechnology, USA) for 2 h at 
37°C and developed by adding 200 μl/well of 1 mg/ml of alkaline 
phosphatase substrate (Sigma-Aldrich). The optical density was 
recorded using a Multiskan FC Microplate Photometer (Thermo 
Scientific). Antibody titers were expressed as the reciprocal of 
the highest dilution with an OD value ≥  0.2 after background 
subtraction.
Bioinformatic analysis
Raw reads were aligned to mouse genome (UCSD mm10 annota-
tion), and counts were generated using STAR (41). Differential 
gene expression was determined using edgeR (42) with the 
generalized linear model (GLM) fitting approach for both longi-
tudinal analysis and pairwise adjuvanted versus non-adjuvanted 
vaccine comparisons at each time point. For each comparison, 
edgeR generated a list of genes associated with a log fold-change 
and to a false discovery rate (FDR, i.e., the P value after multiple 
test correction). Genes were considered significantly differen-
tially expressed when FDR was <0.05. For enrichment analysis, 
lists of genes were sorted by FDR, then mouse gene identifiers 
were converted to human gene identifiers using an in house 
script utilizing the BiomaRt Bioconductor package. Enrichment 
analysis was performed using the tmod R package (43) with blood 
transcription modules (BTMs) developed by Li and coworkers 
(19). Significance of module enrichment was assessed using 
the CERNO statistical test (a modification of Fisher’s combined 
probability test) and corrected for multiple testing using the 
Benjamini–Hochberg correction.
statistical analysis
Analysis was performed on individual samples, and data were 
reported in box plots encompassing minimum and maximum 
values. The Kruskal–Wallis test, followed by Dunn’s post test for 
multiple comparison, was used to assess statistical differences 
among the number of (i) Ag85B-specific CD4+ T  cells, (ii) 
germinal center B cells, and (iii) H56-specific ASC in different 
groups of mice (naïve, primed with antigen H56 alone or primed 
with H56 + CAF01). H56-specific IgG were reported in graphs 
as log-transformed geometric mean titers with 95% confidence 
intervals and compared using t-test. Statistical significance was 
defined as P < 0.05, and analyses were performed using Graph 
Pad Prism version 7 (GraphPad Software, USA).
resUlTs
antigen-specific cD4+ T-cell response
Antigen-specific CD4+ T cell responses were analyzed in mice 
primed with the chimeric TB vaccine antigen H56 administered 
alone or in combination with the liposome system CAF01, and 
boosted after 4 weeks with H56 antigen alone (Figure 1). T cell 
responses were characterized 10  days after boosting (day 38) 
within the local dLN. CD4+ T  cells specific for the immuno-
dominant epitope Ag85B, part of the H56 fusion protein, were 
identified using Ag85B280–294-complexed MHC class II tetramers. 
Staining specificity of Ag85B280–294-complexed MHC class II 
tetramers was determined using a control tetramer complexed 
with an unrelated antigen, which showed a level of staining 
below 0.02% (data not shown). Ten days after booster immuni-
zation with H56 antigen, the number of tetramer-binding CD4+ 
T cells in dLN was about 66,000 (±39,000) in mice primed with 
H56 + CAF01. This was significantly higher than the amount 
of antigen-specific CD4+ T cells present in mice primed with 
the H56 antigen alone (8,260 ±  6,000, P <  0.01, Figure  2A). 
The percentage of antigen-specific CD4+ T  cells in respect 
to total activated CD4+ T cells was 0.55% and 0.07% in mice 
primed with H56 + CAF01 and H56 antigen alone, respectively 
(P < 0.05, data not shown). These data show that inclusion of 
CAF01 in the priming formulation induces an antigen-specific 
proliferation of CD4+ T  cells which is not observed with the 
antigen alone.
characterization of the B-cell response
B cells responses were characterized 10 days after boosting (day 
38) within the local dLN and spleen. Similar to the CD4+ T recall 
response, the reactivation of the B cell response was significantly 
higher in mice that had been primed with H56 + CAF01 com-
pared with H56-primed mice (Figure 2B). Indeed, a significant 
expansion of the B220+ GL7+ CD95+ germinal center B cells 
(GC-B  cells) 10  days following booster immunization was 
measured in mice primed with the CAF01 adjuvant (P <  0.05 
versus H56-primed mice, P < 0.01 versus naïve mice), while the 
amount of cells detected in mice primed with H56 alone was not 
significantly higher compared with naïve mice (Figure 2B). The 
observed GC-B cells response is clearly a recall response of cells 
elicited by the primary immunization, since we have previously 
demonstrated that primary immunization with H56 alone does 
not stimulate the germinal center reaction, while the CAF01 
adjuvant is a strong promoter of this reaction (4).
The induction of antigen-specific IgG antibody responses was 
also assessed at different time points after priming and boosting 
(Figure  2C). The IgG response elicited by both H56 alone or 
combined with CAF01 was very similar at 12 days after priming, 
while a significantly higher response was observed at day 28 and 
FigUre 2 | Adaptive immune response following booster immunization. C57BL/6 mice were subcutaneously immunized as reported in Figure 1. dLN were 
collected 10 days after booster immunization and analyzed for the T and B recall responses. (a) Number of Ag-specific CD4+ T cells, identified as CD4+ CD44+ 
tetramer Ag85B-specific cells. Mean values ± SEM of five mice per group are reported. (B) Number of germinal center B cells, identified as GL7+ CD95+ among 
B220+ B cells in dLN. (c) H56-specific serum IgG titers determined on days 0, 14, 28, 38, 56, and 77 following priming, by ELISA. Antibody titers values are 
reported as GMT ± 95% CI of five mice per group. Arrow indicates day 28 that is the time of boosting. (D) H56-specific antibody-secreting cells (ASC) detected in 
spleens by ELISPOT assay. Kruskal–Wallis test was used to assess statistical differences between groups of mice primed with H56 + CAF01 versus H56 alone 
(*P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001).
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maintained 10 days after boosting in mice primed with antigen 
and adjuvant compared with animals primed with antigen alone 
(day 38, P <  0.001). This was further confirmed by assessing 
antigen-specific ASC in the spleen collected 10 days after booster 
immunization (Figure  2D). The number of H56-specific ASC 
was higher in mice primed with H56 + CAF01 compared with 
animals primed with H56 alone with mean values of 51 and 20, 
respectively.
Blood gene expression compared  
With Pre-immunization and  
Pre-Boost Baselines
The molecular signature of the vaccine formulations was ana-
lyzed in mice primed with H56 alone or in combination with 
CAF01, and boosted with H56 antigen alone (Figure  1). The 
transcriptomic profile was followed over time (without sacrific-
ing the animals), sequencing blood RNA samples collected at 
early time points (1, 2, and 7 days) after primary and secondary 
immunizations (4 samples/each time point). An average of 7.2 µg 
total RNA/sample (range 1.473–60.552 μg/sample, as quantified 
by fluorimetry) was obtained. The isolated RNA was generally 
of high quality, with an average RNA Integrity number of 9.05 
(range 5.8–9.9), as measured by the Bioanalyzer, and a mean 
260/280 absorbance ratio of 2.17.
Gene expression in the blood of mice primed either with 
H56  +  CAF01 or H56 alone was first compared with gene 
expression in blood collected before immunization. In Figure 3 
the left column reports bivariate plots showing differences in 
gene expression between the H56  +  CAF01 and H56 alone 
FigUre 3 | Comparisons of gene expression changes elicited by H56 and H56 + CAF01 vaccine formulations. Each bivariate plot illustrates the comparison at one 
time point, as indicated. For the post-prime time points, the comparisons are represented relative to the naïve baseline. For post-boost time points, the baseline is 
the pre-boost time point. Axes represent log 2 of baseline-normalized expression values. Each dot represents a gene, and colored lines indicate the density of dots 
on the graph. Only genes significantly regulated (FDR < 0.05) by at least one vaccine were included and plotted. Numbers indicate the number of genes included in 
areas indicated by solid black lines. Dashed red lines indicate 0 values (no change in gene expression). Functional analysis was done using Reactome database, and 
representative significantly enriched pathways are included in captions under each plot.
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TaBle 1 | Number of differentially expressed genes in CAF01 adjuvanted mice.
h56 + caF01 versus h56 Upregulated genes Downregulated genes De genes (%) Unaffected genes
Post-priming Day 1 0 0 0 (0) 12,340
Day 2 191 83 274 (2.2) 12,066
Day 7 7 10 17 (0.1) 12,323
Post-boosting Day 1 827 168 995 (8.1) 11,345
Day 2 134 59 193 (1.6) 12,147
Day 7 269 490 759 (6.2) 11,581
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immunized mice at each time point. Differentially expressed 
genes were subjected to functional analysis using the Reactome 
database.1
At day 1 after priming, 39 genes were found to be upregulated, 
while 1,147 genes were downregulated by both formulations. The 
gene modulation was essentially limited to pathways of platelet 
function adhesion, activation and degranulation, and clotting, 
as expected for injection and repeated bleeding of mice. At day 
2 after priming, 143 genes were upregulated, while 1,031 genes 
were downregulated. Among the upregulated genes there was an 
activation of pathways related to innate immunity, neutrophils 
degranulation and IL4-IL13 signaling. At day 7, 124 genes were 
upregulated, and 588 were downregulated by both vaccines. 
Overall, the transcriptomic response was very consistent between 
the two vaccine formulations.
Four weeks after priming, both groups of mice received a 
booster immunization with H56 antigen alone. The day before 
booster immunization, blood was collected from both groups of 
mice, and gene expression analysis performed at this time point 
was then used as a baseline. Gene expression in the blood of mice 
primed with H56 + CAF01 or H56 alone and boosted with H56 
was indeed compared with gene expression in blood collected 
in the same group of mice before booster immunization. In the 
right column of Figure 3 bivariate plots show differential gene 
expression at 1, 2, and 7 days after H56 boosting.
Among the genes upregulated 1 day after H56 boost in mice 
primed with H56 + CAF01, we observed an over representation 
of genes relevant to innate immune response, centered primar-
ily on the interferon response, as well as IL4 and IL13 signaling. 
Importantly, these genes were regulated almost exclusively in 
the H56 +  CAF01 primed group, but not in the group that 
received H56 alone as priming. Two days after boost, only a 
few genes were found to be differentially expressed, and, again, 
as at day 1 post boost, gene regulation was observed primarily 
in the H56 +  CAF01 primed group, but not in the group of 
mice primed with the antigen alone. Interestingly, according to 
the Reactome analysis, the upregulated genes were enriched in 
M. tuberculosis response genes; however, due to the very small 
number of genes regulated at this time point, these results 
should be taken with caution. By 7  days after the boost, the 
two groups displayed a similar gene expression pattern, mainly 
related to genes involved in cell cycle and proliferation, suggest-
ing the activation of an adaptive response and clonal expansion 
of responding antigen-specific cells (Figure 3, right column).
1 https://reactome.org/ (Accessed: November 20, 2017).
effect of caF01 adjuvant on gene 
expression
To identify the CAF01-specific transcriptomic response, the blood 
gene expression in mice primed with H56 + CAF01 was compared 
with that of mice primed with H56 alone. All comparisons were 
performed at 1, 2, and 7 days after priming and after H56 boost. 
Table 1 reports the number of differentially expressed genes iden-
tified in edgeR by the genewise Negative Binomial Generalized 
Linear Models algorithm. Lists of genes, sorted by FDR, were 
converted to human IDs and tested for the significance in the 
enrichment of BTMs (19). BTMs include 346 sets of genes which 
are coordinately expressed and exert a specific function, described 
by the module title, including innate and adaptive immunity or 
general biological processes such as cell cycle, transcription or 
signal transduction. Figure 4 reports modules that were found to 
be significantly enriched (FDR < 0.001) in at least one tested time 
point. Data analysis at days 1, 2, and 7 after priming indicated that 
the major differences between the two vaccine formulations were 
detected at day 2, with 2.2% of differentially expressed genes and 
upregulation of modules related to innate immunity by the CAF01 
adjuvanted vaccine formulation. In particular, modules related to 
antigen-presenting cells (monocytes and DCs) were found to be 
enriched, together with neutrophils and TLR inflammatory signal-
ing. Differential gene expression analysis found no significant dif-
ference between H56 + CAF01 and H56 alone vaccinated groups at 
day 1, and only 17 significant genes at day 7 (Table 1). Nevertheless, 
module enrichment analysis identified seven enriched modules at 
day 1 and one module at day 7. These modules were also related 
to innate immune response, indicating that CAF01 modulates the 
transcriptomic response also at those time points.
The most significant differences between the two vaccine 
formulations could be appreciated after antigen boost, thus 
demonstrating the key role of the boost in highlighting the 
skewing of the immune system induced by the adjuvant used for 
priming. In fact, at day 1 after boost, 34 out of the 44 significant 
modules were modulated by CAF01, with 8.1% of genes being dif-
ferentially expressed (Figure 4; Table 1). In particular, the innate 
immunity compartment was found to be affected: 10 modules 
regarding monocytes and antigen presentation, three modules 
associated with neutrophil recruitment and six modules related 
to interferon response were upregulated, while one module 
associated with natural killer (NK) cells was downregulated. No 
enrichment of modules related to B- and T-cell populations was 
observed at this early time point. At day 2 after boost, the overall 
difference between the two formulations was lower: 13 modules 
were significantly enriched, mainly related to innate response 
with a minor modulation of B cells. Seven days after the boost, 
FigUre 4 | Activation of blood transcription modules (BTMs) by the CAF01 adjuvant. Each column represents a pairwise comparison between blood RNA samples 
from mice primed with H56 + CAF01 versus H56 alone. Both groups were boosted after 4 weeks with H56 alone. Blood samples were collected 1, 2, and 7 days 
after priming and after boosting. Activation of modules was tested using the FDR-ranked lists of genes generated by edgeR generalized linear model fitting and 
applying the CERNO test. Rows indicate different BTMs, which were significantly (FDR < 0.001) activated in at least one time point. Each module is represented by 
a pie in which the proportion of significantly upregulated and downregulated genes is shown in red and blue, respectively. The gray portion of the pie represents 
genes that are not significantly differentially regulated. The significance of module activation is proportional to the intensity of the pie, while the effect size (area under 
the curve) is proportional to its size.
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despite the relatively high number of differentially expressed 
genes (Table 1), only eight modules were affected (Figure 4). In 
particular, these were regarding adaptive immune response with 
three upregulated modules regarding T cell activation and one 
downregulated relevant to B cells activities.
DiscUssiOn
Adjuvants have been extensively employed in vaccinology to 
enhance the immune responses to the antigen and promote the 
strength and persistence of the resulting immunity. Transcriptomic 
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profiling of the immune response induced by vaccine adjuvants 
can contribute understanding the mechanism of action of adju-
vants and guide the rational design of prime-boost vaccination 
strategies. A systems biology approach has been recently applied 
to profile priming properties of different vaccine adjuvants in a 
preclinical model using genome wide microarrays (24) and to 
analyze the response to adjuvanted and unadjuvanted influenza 
vaccines in human studies (18, 19). A clinical study performed 
on young children vaccinated with TIV vaccine administered 
with or without MF-59 adjuvant demonstrated that the inclusion 
of the oil-in-water adjuvant results in a stronger transcriptional 
response at the early time point post vaccination, including a 
higher interferon response, and higher resulting HAI titers (22). 
However, little is understood about the way adjuvants program 
the immune system for the response to re-exposure to the antigen.
In this study, we sought to investigate how the inclusion of the 
adjuvant in the vaccine formulation modifies the way the immune 
system responds to the same antigen, administered at a later time 
without the adjuvant, thus modeling the re-exposure scenario. 
We used mRNA sequencing to profile the mice immune response 
to the vaccine adjuvant CAF01 used in a primary immunization 
followed by a booster immunization with a low dose of H56 
(0.5 μg/mouse) to select antigen-specific clones of T and B cells. 
While we found almost no difference in the transcriptomic profile 
after priming with or without the CAF01 adjuvant, strikingly, the 
effect of the CAF01 adjuvant, used in the primary immunization, 
could be readily appreciated after a booster immunization with 
the vaccine antigen alone. Indeed, we observed a significantly 
stronger upregulation of multiple genes and modules related 
to the innate immune response following boost in mice that 
received the adjuvant with the primary immunization compared 
with the mice that did not. This indicates the potent reprogram-
ming of the immune response to re-exposure by the adjuvant 
included with the primary immunization. Transcriptomics of the 
vaccine immune response highlights therefore that priming with 
adjuvant modulates recall innate responses after boosting. Recent 
studies have reported the capacity of innate immune cells such 
as NK cells, monocytes and macrophages to mount a differential 
immune response upon a secondary contact with the same or 
distinct stimuli (44, 45). This concept of “memory” related to cells 
of the innate immune system is revolutionizing our knowledge of 
the immune system, and could represent an important goal for 
future vaccination strategies, based on the interaction between 
adjuvants and innate cells. Our analysis, performed on the whole 
blood level, does not permit us to dissect the underlying mecha-
nisms of the observed differential response, nevertheless, a new 
study that will include sorting of the innate cell subpopulations 
and transcriptional profiling of the isolated populations, is cur-
rently in the development phase.
In this study, we extracted total RNA from small volumes of 
whole blood to make a longitudinal analysis of the transcrip-
tomic response in the same animals bled multiple times during 
the course of the experiment. This study design and technical 
approach has been previously employed only in few studies 
(39, 40) and has proved the benefit of longitudinal observation 
within the same animal allowing analysis of gene modulation 
over time. An unexpected limitation introduced by this approach 
related to the fact that transcripts that we found to be regulated in 
response to the primary immunization were strongly enriched in 
genes relevant to platelet activation and aggregation, suggesting 
that the response to wounding may have masked the vaccine-
specific response. Nevertheless we identified day 2 after priming 
and day 1 after boost as optimal time points to analyze the gene 
modulation induced by priming with CAF01 adjuvant compared 
with unadjuvanted vaccine formulation.
While we observed only a moderate differential expression of 
T cell activation modules 7 days after boost, the immunological 
analysis performed 10 days after boosting showed a higher fre-
quency of H56-specific CD4+ T cells and germinal center B cells 
in dLN, a strong H56-specific humoral response and a higher fre-
quency of ASC in spleen of mice primed with H56 + CAF01. We 
and others have previously shown that the presence of the CAF01 
adjuvant combined with the antigen in the vaccine formulation 
used for priming is crucial for the induction of the germinal 
center reaction, assessed by the presence of the T follicular and 
germinal center B cells (4, 46), as well as for a strong T cell medi-
ated immune response with a Th1 and Th17 profile (4, 6, 47).
The induction of germinal center reaction and the antigen-
specific T cell effector function could only be detected in dLN 
or in the spleen, while the corresponding gene networks were 
not detected in whole blood. In fact, the transcriptome perturba-
tion detected in peripheral blood is thought to reflect the overall 
response of the immune system to vaccine stimulation, even if 
it is not possible to detect finely tuned responses or phenomena 
localized in specific lymph nodes.
Taken together, our data suggest that the reprogramming of 
the recall immune response by the adjuvant used for priming 
impinges on both innate and adaptive arms resulting, upon 
boosting, in a stronger recall innate response essential for shaping 
the downstream adaptive response.
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